Cargando…
Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles
Caspase-cleaved proteins are released from disintegrated apoptotic cells and can be detected in the circulation. We here addressed whether caspase-cleaved cytokeratin 18 (CK18-Asp396) can be used as a serum biomarker for assessment of the clinical efficiency of chemotherapy in hormone-refractory pro...
Autores principales: | Kramer, G, Schwarz, S, Hägg, M, Havelka, A Mandic, Linder, S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361322/ https://www.ncbi.nlm.nih.gov/pubmed/16685278 http://dx.doi.org/10.1038/sj.bjc.6603129 |
Ejemplares similares
-
A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer
por: Collins, R, et al.
Publicado: (2006) -
Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
por: Bousquet, G, et al.
Publicado: (2011) -
Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer
por: Galli, L, et al.
Publicado: (2007) -
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study
por: Carles, J, et al.
Publicado: (2007) -
Charting calcium-regulated apoptosis pathways using chemical biology: role of calmodulin kinase II
por: Olofsson, Maria Hägg, et al.
Publicado: (2008)